Evaluation of Choroidal Thickness in Patients with Proliferative and Non-Proliferative Macular Telangiectasia Using Enhanced Depth Imaging Optical Coherence Tomography

References

• Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, Holz FG, Scholl HP. Macular telangiectasia type 2. Prog Retin Eye Res. 2013;34:49–77. doi:10.1016/j.preteyeres.2012.11.002.
   PubMed Web of Science ®Google Scholar
• Chhablani JK, Narayanan R. Fundus autofluorescence patterns in type 2A idiopathic juxtafoveolar retinal telangiectasis. Eur J Ophthalmol. 2012;22(3):398–403. doi:10.5301/ejo.5000008.
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Holz FG, Scholl HP. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology. 2007;114(9):1736–42. doi:10.1016/j.ophtha.2007.03.079.
   PubMed Web of Science ®Google Scholar
• Narayanan R, Majji AB, Hussain N, Hussain A, Jalali S, Mathai A, Shah VA. Characterization of idiopathic macular telangiectasia type 2 by fundus fluorescein angiography in Indian population. Eur J Ophthalmol. 2008;18(4):587–90. doi:10.1177/112067210801800414.
   PubMed Web of Science ®Google Scholar
• Gaudric A, Ducos de Lahitte G, Cohen SY, Massin P, Haouchine B. Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol. 2006;124(10):1410–19. doi:10.1001/archopht.124.10.1410.
   PubMedGoogle Scholar
• Cohen SM, Cohen ML, El-Jabali F, Pautler SE. Optical coherence tomography findings in nonproliferative group 2A idiopathic juxtafoveal retinal telangiectasis. Retina. 2007;27(1):59–66. doi:10.1097/01.iae.0000256663.94734.e1.
   PubMed Web of Science ®Google Scholar
• Gass JD. Histopathologic study of presumed parafoveal telangiectasis. Retina. 2000;20(2):226–27. doi:10.1097/00006982-200002000-00028.
   PubMed Web of Science ®Google Scholar
• Potter MJ, Szabo SM, Chan EY, Morris AHC. Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol. 2002;133(1):149–51. doi:10.1016/s0002-9394(01)01205-3.
   PubMed Web of Science ®Google Scholar
• Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa MJ, Harrington MW, MacTel Research Group. Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel project report no. 2. Ophthalmic Epidemiol. 2010;17(1):66–73. doi:10.3109/09286580903450361.
   PubMed Web of Science ®Google Scholar
• Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993;100:1536–46.
   PubMed Web of Science ®Google Scholar
• Switzer DW Jr1, Mendonça LS, Saito M, Zweifel SA, Spaide RF. Segregation of ophthalmoscopic characteristics according to choroidal thickness in patients with early age-related macular degeneration. Retina. 2012;32(7):1265–71. doi:10.1097/IAE.0b013e31824453ac.
   PubMed Web of Science ®Google Scholar
• Chhablani J, Kozak I, Jonnadula GB, Venkata A, Narayanan R, Pappuru RR, Rao PS. Choroidal thickness in macular telangiectasia type 2. Retina. 2014;34(9):1819–23. doi:10.1097/IAE.0000000000000180.
   PubMed Web of Science ®Google Scholar
• Nunes RP, Goldhardt R, de Amorim Garcia Filho CA, Thorell MR, Abbey AM, Kuriyan AE, Modi YS, Shah M, Yehoshua Z, Gregori G, et al. Spectral-domain optical coherence tomography measurements of choroidal thickness and outer retinal disruption in macular telangiectasia type 2. Ophthalmic Surg Lasers Imaging Retina. 2015;46(2):162–70. doi:10.3928/23258160-20150213-17.
   PubMed Web of Science ®Google Scholar
• Kumar V, Kumawat D, Kumar P. Swept source optical coherence tomography analysis of choroidal thickness in macular telangiectasia type 2: a case-control study. Graefes Arch Clin Exp Ophthalmol. 2019 Mar;257(3):567–73. doi:10.1007/s00417-018-04215-9.
   PubMed Web of Science ®Google Scholar
• Baz Ö, Yılmaz İ, Alagöz C, Demircan A, Perente İ, Özkaya A, Taşkapılı M. Efficacy of intravitreal bevacizumab in treatment of proliferative type 2 idiopathic juxtafoveal telangiectasia. Turk J Ophthalmol. 2017 Jun;47(3):144–48. doi:10.4274/tjo.04874.
   PubMedGoogle Scholar
• Heeren TFC, Kitka D, Florea D, Clemons TE, Chew EY, Bird AC, Pauleikhoff D, Charbel Issa P, Holz FG, Peto T. Longitudinal correlation of ellipsoid zone loss and functional loss in macular telangiectasia type 2. Retina. 2018 Jan;38(Suppl 1):S20–S26. doi:10.1097/IAE.0000000000001715.
   PubMedGoogle Scholar
• Kupitz EH, Heeren TF, Holz FG, Charbel Issa P. Poor long-term outcome of anti-vascular endothelial growth factor therapy in nonproliferative macular telangiectasia type 2. Retina. 2015 Dec;35(12):2619–26. doi:10.1097/IAE.0000000000000715.
   PubMed Web of Science ®Google Scholar
• Peto T, Heeren TFC, Clemons TE, Sallo FB, Leung I, Chew EY, Bird AC. Correlatıon of clinical and structural progression with visual acuity loss in macular telangiectasia type 2: MacTel project report no. 6-the MacTel research group. Retina. 2018 Jan;38(Suppl 1):S8–S13. doi:10.1097/IAE.0000000000001697.
   PubMedGoogle Scholar
• Len AC, Powner MB, Zhu L, Hageman GS, Song X, Fruttiger M, Gillies MC. Pilot application of iTRAQ to the retinal disease macular telangiectasia. J Proteome Res. 2012;11(2):537–53. doi:10.1021/pr200889t.
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B. Idiopathic macular telangiectasia. Arch Ophthalmol. 2006;124(4):450–60. doi:10.1001/archopht.124.4.450.
   PubMedGoogle Scholar
• Sallo FB, Peto T, Egan C, Wolf-Schnurrbusch UE, Clemons TE, Gillies MC, Pauleikhoff D, Rubin GS, Chew EY, Bird AC, MacTel Study Group. En face OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci. 2012;53(10):6145–52. doi:10.1167/iovs.12-10580.
   PubMed Web of Science ®Google Scholar
• Linsenmeier RA, Padnick-Silver L. Metabolic dependence of photoreceptors on the choroid in the normal and detached retina. Invest Ophthalmol Vis Sci. 2000;41:3117–23.
   PubMed Web of Science ®Google Scholar
• Melrose MA, Magargal LE, Goldberg RE, Annesley WH Jr. Subretinal neovascular membranes associated with choroidal nonperfusion and retinal ischemia. Ann Ophthalmol. 1987;19:396–99.
   PubMedGoogle Scholar
• Zhang Q, Wang RK, Chen CL, Legarreta AD, Durbin MK, An L, Sharma U, Stetson PF, Legarreta JE, Roisman L, et al. Swept source optical coherence tomography angiography of neovascular macular telangiectasia type 2. Retina. 2015;35(11):2285–99. doi:10.1097/IAE.0000000000000840.
   PubMed Web of Science ®Google Scholar
• Gupta P, Sidhartha E, Girard MJ, Mari JM, Wong TY, Cheng CY. A simplified method to measure choroidal thickness using adaptive compensation in enhanced depth imaging optical coherence tomography. PLoS One. 2014;9(5):e 96661. doi:10.1371/journal.pone.0096661. eCollection 2014.
   Web of Science ®Google Scholar
• Razavi S, Souied EH, Darvizeh F, Querques G. Assessment of choroidal topographic changes by swept-source optical coherence tomography after intravitreal ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol. 2015;160(5):1006–13. doi:10.1016/j.ajo.2015.08.009.
   PubMed Web of Science ®Google Scholar
• Padrón-Pérez N, Arias L, Rubio M, Lorenzo D, García-Bru P, Català-Mora J, Caminal JM. Changes in choroidal thickness after intravitreal injection of anti-vascular endothelial growth factor in pachychoroid neovasculopathy. Invest Ophthalmol Vis Sci. 2018;59(2):1119–24. doi:10.1167/iovs.17-22144.
   PubMed Web of Science ®Google Scholar